Pain Research and Management / 2017 / Article / Tab 3

Clinical Study

Efficacy and Safety of Transdermal Buprenorphine versus Oral Tramadol/Acetaminophen in Patients with Persistent Postoperative Pain after Spinal Surgery

Table 3

Quality of life and treatment satisfaction scores.

Full analysis setBuprenorphine transdermal system ()Oral tramadol/acetaminophen
()
value (-test)

EQ-5D index, mean ± SD
 Baseline (week 0)0.57 ± 0.130.46 ± 0.27
 Week 6 (LOCF)0.68 ± 0.180.65 ± 0.14
 Improvement (week 0 to week 6)0.10 ± 0.190.19 ± 0.210.0258
value (paired test)0.0004<0.0001
EQ-5D-3L dimension scores
 (1) Mobility
  Baseline (week 0)0.86 ± 0.080.85 ± 0.110.7111
  Week 6 (LOCF)0.89 ± 0.030.88 ± 0.030.6256
  Improvement (week 0 to week 6)0.03 ± 0.080.03 ± 0.110.8326
   value (paired test)0.00800.0281
 (2) Self-care
  Baseline (Week 0)0.83 ± 0.070.78 ± 0.140.0161
  Week 6 (LOCF)0.87 ± 0.050.84 ± 0.070.0108
  Improvement (week 0 to week 6)0.04 ± 0.080.06 ± 0.130.3247
   value (paired test)0.00080.0021
 (3) Usual activities
  Baseline (week 0)0.88 ± 0.010.82 ± 0.140.0007
  Week 60.89 ± 0.020.89 ± 0.050.6431
  Improvement (Week 0 to Week 6)0.01 ± 0.010.07 ± 0.130.0006
   value (paired test)0.00190.0002
 (4) Pain/discomfort
  Baseline (week 0)0.80 ± 0.020.78 ± 0.100.1245
  Week 6 (LOCF)0.81 ± 0.090.82 ± 0.050.6831
  Improvement (week 0 to week 6)0.01 ± 0.090.04 ± 0.120.1731
   value (paired test)0.29400.0158
 (5) Anxiety/depression
  Baseline (Week 0)0.88 ± 0.040.88 ± 0.080.8932
  Week 6 (LOCF)0.89 ± 0.070.90 ± 0.030.5537
  Improvement (week 0 to week 6)0.01 ± 0.080.02 ± 0.070.6613
   value (paired test)0.18650.0479
Treatment satisfaction scores at week 6, mean ± SD
 CGIC2.46 ± 1.282.37 ± 0.980.7067
 PGIC2.53 ± 1.282.39 ± 0.920.5304

of life (EQ-5D-3L, Korean version): consists of 5 items, that is, mobility, self-care, normal activities, pain/discomfort, and anxiety/depression. EQ-5D-3L scores were computed according to Table 1; , PGIC: Clinical Global Impression of Change, Patient Global Impression of Change. 1 = very much improved since the initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline (the initiation of treatment); 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment. values < 0.05 are marked in bold text.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.